McKesson Corporation maintains a 'Hold' rating as its shares trade at a premium with limited upside to a $1,115 target price. The company benefits from strong demand for specialty drugs and services, though expansion of GLP-1 coverage is slow and synergies from recent acquisitions will take time to materialize. Management has raised its adjusted EPS guidance for 2027 to $45.60–46.40, expecting profit growth to outpace revenue. The company also plans robust capital returns, including a $5 billion buyback program through 2027, low leverage, and dividend increases, but further portfolio additions are recommended only after a correction of more than 10%.
McKesson shares trade at USD 1,098.95 on Pluang, showing a 2.03% gain as of Nov 13, 2026 23:31 WIB. Despite the premium price, all current Pluang order activity is selling, reflecting cautious sentiment among investors.
